Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability.

Trotta T ¹,

Fasanella A ,

Scaltrito D ,

Gradoni L ,

Affiliations

1. Dipartimento di Scienze Biomediche, University of Foggia, Ospedali Riuniti, Italy.
Authors
Trotta T¹
(1 author)

Comparative Immunology, Microbiology and Infectious Diseases, 12 Jan 2010, 33(2):175-182
https://doi.org/10.1016/j.cimid.2009.12.003 PMID: 20061026

Abstract

The aim of this study was to evaluate, in terms of dog macrophage killing ability in vitro, a vaccine based on Leishmania infantum promastigote soluble antigen (LSA) formulated with three different adjuvants (BCG, AdjuPrime, MPL/TDM/CWS). A significant increase of the macrophage killing ability was observed in dogs vaccinated with LSA+MPL/TDM/CWS after 1 month from vaccination. A similar increase of macrophage parasitocidal ability was present only after 5 months in dogs vaccinated with LSA+BCG or LSA+AdjuPrime. In all dogs the augmented killing percentage was still present after 12 months from vaccination. Therefore, in particular LSA+MPL/TDM/CWS vaccine seems promising for further studies in dogs.

Full text links

Read article at publisher's site: https://doi.org/10.1016/j.cimid.2009.12.003

References

Articles referenced by this article (33)

Sabotage and exploitation in macrophages parasitized by intracellular protozoans.
Denkers EY, Butcher BA
Trends Parasitol, (1):35-41 2005
MED: 15639739
Infection with Leishmania infantum Inhibits actinomycin D-induced apoptosis of human monocytic cell line U-937.
Lisi S, Sisto M, Acquafredda A, Spinelli R, Schiavone M, Mitolo V, Brandonisio O, Panaro M
J Eukaryot Microbiol, (3):211-217 2005
MED: 15926996
Canine leishmaniasis in the Gargano promontory (Apulia, South Italy).
Brandonisio O, Carelli G, Ceci L, Consenti B, Fasanella A, Puccini V
Eur J Epidemiol, (2):273-276 1992
MED: 1644148
The current status of zoonotic leishmaniases and approaches to disease control.
Gramiccia M, Gradoni L
Int J Parasitol, (11-12):1169-1180 2005
MED: 16162348
Incidences of canine leishmaniasis in an endemic area of southern Italy.
Paradies P, Capelli G, Cafarchia C, de Caprariis D, Sasanelli M, Otranto D
J Vet Med B Infect Dis Vet Public Health, (6):295-298 2006
MED: 16907963
Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons.
Oliva G, Scalone A, Foglia Manzillo V, Gramiccia M, Pagano A, Di Muccio T, Gradoni L
J Clin Microbiol, (4):1318-1322 2006
MED: 16597857
Leishmania vaccines: progress and problems.
Kedzierski L, Zhu Y, Handman E
Parasitology, S87-112 2006
MED: 17274851
Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.
Fujiwara RT, Vale AM, Franca da Silva JC, da Costa RT, Quetz Jda S, Martins Filho OA, Reis AB, Correa Oliveira R, Machado-Coelho GL, Bueno LL, Bethony JM, Frank G, Nascimento E, Genaro O, Mayrink W, Reed S, Campos-Neto A
Vet Res, (5-6):827-838 2005
MED: 16120256
The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.
Saraiva EM, de Figueiredo Barbosa A, Santos FN, Borja-Cabrera GP, Nico D, Souza LO, de Oliveira Mendes-Aguiar C, de Souza EP, Fampa P, Parra LE, Menz I, Dias JG Jr, de Oliveira SM, Palatnik-de-Sousa CB
Vaccine, (13):2423-2431 2005
MED: 16386824
Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.
Lemesre JL, Holzmuller P, Goncalves RB, Bourdoiseau G, Hugnet C, Cavaleyra M, Papierok G
Vaccine, (21):4223-4234 2007
MED: 17395339

Show 10 more references (10 of 33)

Citations & impact

Impact metrics

Citations

Jump to Citations

Article citations

Preparation of graphene oxide-stabilized Pickering emulsion adjuvant for Pgp3 recombinant vaccine and enhanced immunoprotection against Chlamydia Trachomatis infection.
Zhao L, Shu M, Chen H, Shi K, Li Z
Front Immunol, 14:1148253, 18 Apr 2023
Cited by: 1 article | PMID: 37143655 | PMCID: PMC10152066
This article is in the Europe PMC Open access subset. Refer to the copyright information in the article for licensing details.
Free full text in Europe PMC
Current status on prevention and treatment of canine leishmaniasis.
Reguera RM, Morán M, Pérez-Pertejo Y, García-Estrada C, Balaña-Fouce R
Vet Parasitol, 227:98-114, 12 Jul 2016
Cited by: 46 articles | PMID: 27523945
Review

Search life-sciences literature (45,094,167 articles, preprints and more)

Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability.

Affiliations

Abstract

Full text links

References

Sabotage and exploitation in macrophages parasitized by intracellular protozoans.

Infection with Leishmania infantum Inhibits actinomycin D-induced apoptosis of human monocytic cell line U-937.

Canine leishmaniasis in the Gargano promontory (Apulia, South Italy).

The current status of zoonotic leishmaniases and approaches to disease control.

Incidences of canine leishmaniasis in an endemic area of southern Italy.

Incidence and time course of Leishmania infantum infections examined by parasitological, serologic, and nested-PCR techniques in a cohort of naive dogs exposed to three consecutive transmission seasons.

Leishmania vaccines: progress and problems.

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

The FML-vaccine (Leishmune) against canine visceral leishmaniasis: a transmission blocking vaccine.

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.

Citations & impact

Impact metrics

Article citations

Preparation of graphene oxide-stabilized Pickering emulsion adjuvant for Pgp3 recombinant vaccine and enhanced immunoprotection against Chlamydia Trachomatis infection.

Current status on prevention and treatment of canine leishmaniasis.

Similar Articles

Long-lasting protection against canine visceral leishmaniasis using the LiESAp-MDP vaccine in endemic areas of France: double-blind randomised efficacy field trial.

Vaccination of dogs with six different candidate leishmaniasis vaccines composed of a chimerical recombinant protein containing ribosomal and histone protein epitopes in combination with different adjuvants.

Immunogenicity in dogs of three recombinant antigens (TSA, LeIF and LmSTI1) potential vaccine candidates for canine visceral leishmaniasis.

Development of a leishmaniasis vaccine: the importance of MPL.

Partnerships & funding

Search life-sciences literature (45,094,167 articles, preprints and more)

Comparison between three adjuvants for a vaccine against canine leishmaniasis: In vitro evaluation of macrophage killing ability.

Author information

Affiliations

Abstract

Full text links

References

Citations & impact

Impact metrics

Article citations

Similar Articles

Partnerships & funding